Ad
related to: daniel hoyer novartis
Search results
Results From The WOW.Com Content Network
Daniel Lucius Vasella (born 15 August 1953) is a Swiss medical doctor, author, and executive who was CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. [1] [2] During his tenure Novartis shares fell 10%, compared to the industry average.
Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010 [7] by his predecessor and Chairman Daniel Vasella. [8]During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods would help to realize improvements in Novartis ...
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
(Reuters) -Voyager Therapeutics said on Tuesday Swiss-based drugmaker Novartis would pay $100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders.
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the ...
Nestor Daniel Hoyer Angel David Hoyer Freddy Fuentes Efrain Zambrano Angel Zambrano: Los Terrícolas was a Venezuelan pop music group. American music critic Craig ...
He spent eight years working in Novartis Vaccines, and was the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17] From 2014 to 2016, he was the Global Head of Development for Novartis Pharmaceuticals.
Novartis has also stated that the NITD will seek to make treatments developed by the NITD available without profit to the poor in developing nations in which these diseases are endemic. [3] In 2017, NITD moved out of Singapore to be beside Novartis' infectious diseases research headquarters in Emeryville, California, United States. [4]